Developer docs
API playgroundTry for free, no card

Search company profiles

Corealis Pharma

Full company profile

uuid000c663

Namestring
Corealis Pharma
Legal namestring
Corealis Pharma Inc.
Company typeenum
Private
Founded yearint
2005
Descriptiontext

Corealis Pharma Inc. is a privately held Contract Development and Manufacturing Organization (CDMO) headquartered in Laval, Quebec, founded in 2005. The company specializes exclusively in oral solid dosage (OSD) form drug development and Phase I/II GMP clinical manufacturing, operating across two sites totaling more than 60,000 square feet of integrated formulation, analytical, HPAPI-handling (down to approximately 1 µg/m³ exposure), spray drying (500 g/day and 5 kg/batch), and packaging infrastructure. Its service offering is structured as five interconnected modules: pre-formulation/API characterization, formulation development, analytical services, GMP manufacturing, and packaging/labeling with global clinical supply distribution, typically delivering clinical supply within 4–6 months from project kickoff.

Corealis generates revenue through project-based B2B contracts with emerging biotech, mid-sized pharma, and virtual/asset-light biotech clients, supported by a direct sales motion led by a VP of Business Development and active participation in industry conferences (BIO, DDF Summit, AAPS PharmSci 360, BIO-Europe, ChemOutsourcing). Channel reach is augmented by marketplace listings on Science Exchange, Scientist.com, and Prendio-BioProcure. To extend beyond its Phase I/II scope, Corealis has built flagship strategic alliances with Bora Pharmaceuticals (announced December 2025, end-to-end commercial-scale pathway) and Rottendorf Pharma (announced February 2026, transatlantic European commercial supply pathway), positioning the integrated offering from pre-formulation through commercial launch.

The company is institutionally backed by ArchiMed (lead, through its MED III fund) and CDPQ since a 2022 private equity investment, with co-founders Yves Mouget and Patrick Gosselin remaining in VP roles alongside a new CEO, David Leroux-Petersen, and a CFO recruited from Sanofi (Pascal Tougas). Operational metrics cited include 900+ completed studies, 27 commercialized drug products representing over $10 billion in market value, more than 700 clinical trials supported across 28 countries, and a 100% on-time delivery record between 2020 and 2025. Capacity was doubled in 2024 and the company celebrated its 20th anniversary in 2025.

Short descriptiontext

Corealis Pharma is a Canadian CDMO specializing exclusively in oral solid dosage formulation development and Phase I/II GMP clinical manufacturing for emerging biotech, virtual biotech, and pharmaceutical companies, with integrated pre-formulation, analytical, HPAPI handling, and global clinical supply services.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLaval, Canada
HQ citystring
Laval
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
oral solid dosage CDMO, pharmaceutical formulation development, clinical supply manufacturing, GMP tablet encapsulation, pre-formulation analytical services
Industry3 codes
PRIMARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAJ
Packaging, Labeling & Serialization (Clinical/Commercial) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Pharmaceutical CDMO Services (Oral Solid Dosage)
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1CDMO Contract Services
TypeProfessional Services
Description

Corealis Pharma operates as a Contract Development and Manufacturing Organization (CDMO) providing specialized pharmaceutical development and manufacturing services. Revenue is generated through project-based contracts for formulation development, analytical services, GMP manufacturing, and clinical supply packaging. Services are priced per project with quotes provided based on scope and complexity.

corealispharma.com
2Clinical Supply Manufacturing
TypeProfessional Services
Description

Phase-appropriate manufacturing of tablets and capsules for clinical trials, including packaging and labeling services for global clinical trial material distribution.

corealispharma.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain
Pricing details1 tier
1Project-based pricing for CDMO services
ModelOtherBilling cadenceMulti-year contract
Notes

Pricing varies based on service scope: pre-formulation, formulation development, analytical services, GMP manufacturing, and packaging. Quotes are provided per project based on complexity, phases, and volume requirements.

corealispharma.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Corealis Pharma is a Contract Development and Manufacturing Organization (CDMO) that provides formulation development and clinical supplies manufacturing of solid oral dosage forms for biotech and pharmaceutical companies. Its services span OSD pre-formulation (API characterization), formulation development, analytical services, Phase I/II GMP manufacturing of tablets and capsules, and clinical packaging/labeling with global distribution. Typical timelines run 4–6 months from project kickoff to clinical trial supply.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 4-6 months typical timeline from project kickoff to clinical trial supply
+4 more records
Product overview1 text field

Corealis Pharma is a CDMO (Contract Development and Manufacturing Organization) providing integrated oral solid dosage (OSD) development and GMP clinical manufacturing services. The company offers five interconnected service modules: OSD Pre-Formulation (API characterization and compatibility studies), OSD Formulation Development (scalable formulation design), Analytical Services (method development, stability testing, GMP release), GMP Manufacturing (clinical batch production for Phase I/II), and Packaging & Labeling (clinical supply packaging and global distribution). Services are designed to guide molecules from early development through to clinical trial material delivery, with typical timelines of 4-6 months from kickoff to clinical supply.

Product and service5 records
1OSD Pre-Formulation
CategoryPharmaceutical CDMO – Pre-Formulation
Description

API physicochemical characterization services including particle morphology (SEM), particle size distribution (laser diffraction), crystal state analysis (XRPD), thermal analysis (DSC/TGA), hygroscopicity testing (DVS), powder rheology and density testing, and compatibility studies. Designed for biotech and pharma clients preparing an oral solid dose candidate for formulation development.

2OSD Formulation Development
CategoryPharmaceutical CDMO – Formulation Development
Description

Design and optimization of scalable oral solid dosage formulations (immediate, delayed, and sustained release tablets and capsules) tailored to API physicochemical properties and clinical program goals. Built for biotech and pharmaceutical clients advancing complex or poorly soluble molecules into the clinic.

3Analytical Services
CategoryPharmaceutical CDMO – Analytical Services
Description

Comprehensive analytical development and testing including method development, impurity profiling, dissolution testing, stability programs, GMP release testing, and regulatory compliance support. Provided to biotech and pharmaceutical clients requiring analytical evidence underpinning formulation and manufacturing decisions.

4GMP Manufacturing
CategoryPharmaceutical CDMO – GMP Manufacturing
Description

Phase-appropriate manufacturing of tablets and capsules for Phase I and II clinical trials using processes including direct compression, wet and dry granulation, melt granulation, extrusion and spheronization, encapsulation, coating, solid dispersion, and spray drying (500 g/day to 5 kg/batch). Delivered to biotech and pharmaceutical clients with high-potency API handling capability (~1 µg/m3 exposure).

5Packaging & Labeling
CategoryPharmaceutical CDMO – Clinical Packaging & Labeling
Description

Clinical packaging and labeling services including blister packaging, bottling, pouching, blinded study packaging, patient kit preparation, and global clinical trial material distribution. Provided to biotech and pharmaceutical clients running Phase I/II trials worldwide.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-11
Description

Strategic transatlantic alliance for integrated early-to-late-stage OSD development from pre-formulation through commercial supply. Corealis leads R&D and Phase I-II clinical supply while Rottendorf manages Phase III, validation, and commercial manufacturing. Operates under joint execution and governance framework aligning formulation strategy, analytical methods, manufacturing processes, and regulatory expectations. Designed to enable seamless transition from North American clinical development to European Phase III and commercial manufacturing.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-12-09
Description

Strategic alliance announced December 2025 to provide end-to-end oral solid dose development and manufacturing services. The collaboration combines Bora's global commercial infrastructure and scale-up capabilities with Corealis' formulation development and clinical-scale manufacturing expertise. Partners operate as a single integrated team with unified steering committee, shared quality framework, and joint delivery team. The alliance creates a seamless pathway from discovery through commercial launch for biotech and pharmaceutical companies.

Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-06-03
Description

Strategic integration with Prendio procurement platform. Corealis' selective partner vetting ensures only organizations with proven track record of excellence are authorized to offer services through the platform, reflecting commitment to quality and scientific rigor.

Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-04-09
Description

Corealis integrated into the Science Exchange marketplace platform, enabling biotech companies to easily initiate proposal requests, align projects, manage communication, and ensure procurement compliance through a centralized online marketplace.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Recipharm
TypeDirect peer
Description

European-headquartered CDMO with strong OSD capabilities across clinical and commercial supply. Directly comparable in service offering and biotech customer focus, though operates larger commercial-scale facilities across multiple geographies.

TypeBroad incumbent
Description

Global CDMO within Thermo Fisher providing drug substance and drug product development, including OSD clinical manufacturing and commercial supply. Comparable in service scope but vastly larger and part of a broader life sciences platform.

TypeDirect peer
Description

European CDMO specializing in solid dosage forms including tablets, capsules, and complex formulations. Closely comparable to Corealis in OSD specialization and biotech-to-pharma customer mix.

TypeDirect peer
Description

US-based CDMO focused on OSD formulation, analytical services, and GMP clinical manufacturing for Phase I/II. Closely comparable niche specialist in early-phase OSD CDMO services.

TypeBroad incumbent
Description

Global CDMO offering drug development, manufacturing, and clinical trial material services including OSD. Comparable service scope with broader clinical packaging and commercial manufacturing footprint.

TypeBroad incumbent
Description

Swiss-headquartered global CDMO with both small molecule and biologics capabilities. Overlaps with Corealis on OSD clinical manufacturing but operates at global scale with much broader modality coverage.

TypeBroad incumbent
Description

One of the largest global CDMOs offering OSD formulation, clinical and commercial manufacturing, and packaging. Direct overlap with Corealis on Phase I/II OSD services, but Catalent operates at significantly larger scale across multiple sites and modalities.

TypeDirect peer
Description

European CDMO specializing in OSD development and commercial manufacturing. Corealis' strategic alliance partner and directly comparable specialist in OSD CDMO services with European market focus.

TypeDirect peer
Description

CDMO providing API and drug product development/manufacturing including OSD capabilities. Comparable mid-sized CDMO with similar biotech-to-pharma customer base, though with stronger API offering than Corealis.

TypeDirect peer
Description

Taiwan-headquartered CDMO with OSD commercial manufacturing scale. Corealis' strategic alliance partner and direct peer in OSD services, though Bora's strength is in commercial-scale rather than early clinical manufacturing.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI capability1 record

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Corealis Pharma

Pharmaceutical CDMO Services (Oral Solid Dosage)corealispharma.com

Corealis Pharma is a Canadian CDMO specializing exclusively in oral solid dosage formulation development and Phase I/II GMP clinical manufacturing for emerging biotech, virtual biotech, and pharmaceutical companies, with integrated pre-formulation, analytical, HPAPI handling, and global clinical supply services.

What Corealis Pharma does

Corealis Pharma Inc. is a privately held Contract Development and Manufacturing Organization (CDMO) headquartered in Laval, Quebec, founded in 2005. The company specializes exclusively in oral solid dosage (OSD) form drug development and Phase I/II GMP clinical manufacturing, operating across two sites totaling more than 60,000 square feet of integrated formulation, analytical, HPAPI-handling (down to approximately 1 µg/m³ exposure), spray drying (500 g/day and 5 kg/batch), and packaging infrastructure. Its service offering is structured as five interconnected modules: pre-formulation/API characterization, formulation development, analytical services, GMP manufacturing, and packaging/labeling with global clinical supply distribution, typically delivering clinical supply within 4–6 months from project kickoff.

Corealis generates revenue through project-based B2B contracts with emerging biotech, mid-sized pharma, and virtual/asset-light biotech clients, supported by a direct sales motion led by a VP of Business Development and active participation in industry conferences (BIO, DDF Summit, AAPS PharmSci 360, BIO-Europe, ChemOutsourcing). Channel reach is augmented by marketplace listings on Science Exchange, Scientist.com, and Prendio-BioProcure. To extend beyond its Phase I/II scope, Corealis has built flagship strategic alliances with Bora Pharmaceuticals (announced December 2025, end-to-end commercial-scale pathway) and Rottendorf Pharma (announced February 2026, transatlantic European commercial supply pathway), positioning the integrated offering from pre-formulation through commercial launch.

The company is institutionally backed by ArchiMed (lead, through its MED III fund) and CDPQ since a 2022 private equity investment, with co-founders Yves Mouget and Patrick Gosselin remaining in VP roles alongside a new CEO, David Leroux-Petersen, and a CFO recruited from Sanofi (Pascal Tougas). Operational metrics cited include 900+ completed studies, 27 commercialized drug products representing over $10 billion in market value, more than 700 clinical trials supported across 28 countries, and a 100% on-time delivery record between 2020 and 2025. Capacity was doubled in 2024 and the company celebrated its 20th anniversary in 2025.

Corealis Pharma firmographics

Firmographics
Name
Corealis Pharma
Legal name
Corealis Pharma Inc.
Website
https://corealispharma.com
Company type
Private
Founded year
2005
Operating status
Operating
Headcount range
11–50 employees
Short description
Corealis Pharma is a Canadian CDMO specializing exclusively in oral solid dosage formulation development and Phase I/II GMP clinical manufacturing for emerging biotech, virtual biotech, and pharmaceutical companies, with integrated pre-formulation, analytical, HPAPI handling, and global clinical supply services.
Ownership category
akta.pro rank

Corealis Pharma industry classification

Industry
Product category
Pharmaceutical CDMO Services (Oral Solid Dosage)
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAJ
Packaging, Labeling & Serialization (Clinical/Commercial) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Oral solid dosage CDMO
  • Pharmaceutical formulation development
  • Clinical supply manufacturing
  • GMP tablet encapsulation
  • Pre-formulation analytical services

Where Corealis Pharma is headquartered

Location

Headquarters

HQ city
Laval
HQ country
Canada
HQ region
North America

Offices2 records

Markets served

Corealis Pharma business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

  1. CDMO Contract Services: Corealis Pharma operates as a Contract Development and Manufacturing Organization (CDMO) providing specialized pharmaceutical development and manufacturing services. Revenue is generated through project-based contracts for formulation development, analytical services, GMP manufacturing, and clinical supply packaging. Services are priced per project with quotes provided based on scope and complexity.
  2. Clinical Supply Manufacturing: Phase-appropriate manufacturing of tablets and capsules for clinical trials, including packaging and labeling services for global clinical trial material distribution.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractProject-based pricing for CDMO services

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Corealis Pharma product offering

Product offering

Core offering

Corealis Pharma is a Contract Development and Manufacturing Organization (CDMO) that provides formulation development and clinical supplies manufacturing of solid oral dosage forms for biotech and pharmaceutical companies. Its services span OSD pre-formulation (API characterization), formulation development, analytical services, Phase I/II GMP manufacturing of tablets and capsules, and clinical packaging/labeling with global distribution. Typical timelines run 4–6 months from project kickoff to clinical trial supply.

Product overview

Corealis Pharma is a CDMO (Contract Development and Manufacturing Organization) providing integrated oral solid dosage (OSD) development and GMP clinical manufacturing services. The company offers five interconnected service modules: OSD Pre-Formulation (API characterization and compatibility studies), OSD Formulation Development (scalable formulation design), Analytical Services (method development, stability testing, GMP release), GMP Manufacturing (clinical batch production for Phase I/II), and Packaging & Labeling (clinical supply packaging and global distribution). Services are designed to guide molecules from early development through to clinical trial material delivery, with typical timelines of 4-6 months from kickoff to clinical supply.

Differentiator

Problem solved

Functional benefit

Products and services

  • OSD Pre-Formulation API physicochemical characterization services including particle morphology (SEM), particle size distribution (laser diffraction), crystal state analysis (XRPD), thermal analysis (DSC/TGA), hygroscopicity testing (DVS), powder rheology and density testing, and compatibility studies. Designed for biotech and pharma clients preparing an oral solid dose candidate for formulation development.
  • OSD Formulation Development Design and optimization of scalable oral solid dosage formulations (immediate, delayed, and sustained release tablets and capsules) tailored to API physicochemical properties and clinical program goals. Built for biotech and pharmaceutical clients advancing complex or poorly soluble molecules into the clinic.
  • Analytical Services Comprehensive analytical development and testing including method development, impurity profiling, dissolution testing, stability programs, GMP release testing, and regulatory compliance support. Provided to biotech and pharmaceutical clients requiring analytical evidence underpinning formulation and manufacturing decisions.
  • GMP Manufacturing Phase-appropriate manufacturing of tablets and capsules for Phase I and II clinical trials using processes including direct compression, wet and dry granulation, melt granulation, extrusion and spheronization, encapsulation, coating, solid dispersion, and spray drying (500 g/day to 5 kg/batch). Delivered to biotech and pharmaceutical clients with high-potency API handling capability (~1 µg/m3 exposure).
  • Packaging & Labeling Clinical packaging and labeling services including blister packaging, bottling, pouching, blinded study packaging, patient kit preparation, and global clinical trial material distribution. Provided to biotech and pharmaceutical clients running Phase I/II trials worldwide.

Quantifiable outcome

  • 4-6 months typical timeline from project kickoff to clinical trial supply
  • +4 more outcomes

Companies that use Corealis Pharma

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Corealis Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature5 records

Corealis Pharma partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core, flagship and minor.

  • Rottendorf PharmacoreStrategic or Co-development Partner · 11 February 2026Strategic transatlantic alliance for integrated early-to-late-stage OSD development from pre-formulation through commercial supply. Corealis leads R&D and Phase I-II clinical supply while Rottendorf manages Phase III, validation, and commercial manufacturing. Operates under joint execution and governance framework aligning formulation strategy, analytical methods, manufacturing processes, and regulatory expectations. Designed to enable seamless transition from North American clinical development to European Phase III and commercial manufacturing.
  • Bora PharmaceuticalsflagshipStrategic or Co-development Partner · 9 December 2025Strategic alliance announced December 2025 to provide end-to-end oral solid dose development and manufacturing services. The collaboration combines Bora's global commercial infrastructure and scale-up capabilities with Corealis' formulation development and clinical-scale manufacturing expertise. Partners operate as a single integrated team with unified steering committee, shared quality framework, and joint delivery team. The alliance creates a seamless pathway from discovery through commercial launch for biotech and pharmaceutical companies.
  • Prendio-BioProcureminorChannel Partner/ Reseller/ Distributor · 3 June 2025Strategic integration with Prendio procurement platform. Corealis' selective partner vetting ensures only organizations with proven track record of excellence are authorized to offer services through the platform, reflecting commitment to quality and scientific rigor.
  • Science ExchangeminorChannel Partner/ Reseller/ Distributor · 9 April 2025Corealis integrated into the Science Exchange marketplace platform, enabling biotech companies to easily initiate proposal requests, align projects, manage communication, and ensure procurement compliance through a centralized online marketplace.

Scale indicators8 records

Recent moves7 records

Expansion highlights5 records

Corealis Pharma competitors and assessment

Company assessment

Direct peers

  • Recipharm: European-headquartered CDMO with strong OSD capabilities across clinical and commercial supply. Directly comparable in service offering and biotech customer focus, though operates larger commercial-scale facilities across multiple geographies.
  • Aenova: European CDMO specializing in solid dosage forms including tablets, capsules, and complex formulations. Closely comparable to Corealis in OSD specialization and biotech-to-pharma customer mix.
  • Metrics Contract Services: US-based CDMO focused on OSD formulation, analytical services, and GMP clinical manufacturing for Phase I/II. Closely comparable niche specialist in early-phase OSD CDMO services.
  • Rottendorf Pharma: European CDMO specializing in OSD development and commercial manufacturing. Corealis' strategic alliance partner and directly comparable specialist in OSD CDMO services with European market focus.
  • Cambrex: CDMO providing API and drug product development/manufacturing including OSD capabilities. Comparable mid-sized CDMO with similar biotech-to-pharma customer base, though with stronger API offering than Corealis.
  • Bora Pharmaceuticals: Taiwan-headquartered CDMO with OSD commercial manufacturing scale. Corealis' strategic alliance partner and direct peer in OSD services, though Bora's strength is in commercial-scale rather than early clinical manufacturing.

Broad incumbents

  • Patheon (Thermo Fisher Scientific): Global CDMO within Thermo Fisher providing drug substance and drug product development, including OSD clinical manufacturing and commercial supply. Comparable in service scope but vastly larger and part of a broader life sciences platform.
  • Almac Group: Global CDMO offering drug development, manufacturing, and clinical trial material services including OSD. Comparable service scope with broader clinical packaging and commercial manufacturing footprint.
  • Lonza: Swiss-headquartered global CDMO with both small molecule and biologics capabilities. Overlaps with Corealis on OSD clinical manufacturing but operates at global scale with much broader modality coverage.
  • Catalent: One of the largest global CDMOs offering OSD formulation, clinical and commercial manufacturing, and packaging. Direct overlap with Corealis on Phase I/II OSD services, but Catalent operates at significantly larger scale across multiple sites and modalities.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Corealis Pharma social profiles

Digital presence

Corealis Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Corealis Pharma leadership team

Management profile

Number of profiles

Profiles8 records

Corealis Pharma funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Corealis Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Corealis Pharma

What does Corealis Pharma do?

Corealis Pharma is a Contract Development and Manufacturing Organization (CDMO) that provides formulation development and clinical supplies manufacturing of solid oral dosage forms for biotech and pharmaceutical companies. Its services span OSD pre-formulation (API characterization), formulation development, analytical services, Phase I/II GMP manufacturing of tablets and capsules, and clinical packaging/labeling with global distribution. Typical timelines run 4–6 months from project kickoff to clinical trial supply.

Is Corealis Pharma a public or private company?

Corealis Pharma is a private company. It is classified as private equity controlled and is currently operating.

When was Corealis Pharma founded?

Corealis Pharma was founded in 2005. It employs 11 to 50 people.

Where is Corealis Pharma based?

Corealis Pharma is headquartered in Laval, Canada, in the North America region.

How does Corealis Pharma make money?

Two revenue lines are on record. CDMO Contract Services are the primary driver. The others are clinical Supply Manufacturing.

Who are Corealis Pharma's main competitors?

Direct peers on record are Recipharm, Aenova, Metrics Contract Services, Rottendorf Pharma, Cambrex and Bora Pharmaceuticals. Broad incumbents are Patheon (Thermo Fisher Scientific), Almac Group, Lonza and Catalent.

Does Corealis Pharma have an API?

No public API is recorded for Corealis Pharma.

What industry is Corealis Pharma in?

Corealis Pharma's product category is Pharmaceutical CDMO Services (Oral Solid Dosage). Its primary akta.pro industry code is HLAGABAB, Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO, with a secondary code of HLAGABAK, Clinical Trial Material (CTM) Manufacturing & Supply CDMO. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business & FinancialPharmala Signs Agreement And Initiates R&D With Corealis Pharma For GMP Manufacturing Of Its Patented ALA-002 Drug ProductPharmala signed an agreement with Corealis Pharma to initiate R&D for GMP manufacturing of its patented ALA-002 drug product. Corealis began formulation work, with the first batch scheduled after development. ALA-002 will initially be developed as a 50mg capsule.Financial PostCorealis Pharma and PhinC Group Collaborate to Bring Predictive Modeling into Early Formulation DevelopmentCorealis Pharma and PhinC Group announced a collaboration to integrate physiologically based biopharmaceutics and pharmacokinetic modeling into oral solid dosage form development. The partnership combines Corealis' formulation expertise with PhinC's predictive modeling to evaluate release rate, solubility, and food effects earlier. The aim is to reduce development risk and guide formulation decisions with greater confidence.FinancialContent Business PageCorealis Pharma and PhinC Group Collaborate to Bring Predictive Modeling into Early Formulation DevelopmentCorealis Pharma and PhinC Group announced a collaboration to integrate PBBM and PBPK modeling into oral solid dosage form development. The partnership combines Corealis' formulation expertise with PhinC's predictive modeling to evaluate factors like solubility and food effects earlier. The aim is to reduce development risk and guide formulation decisions with greater confidence.BioSpaceCorealis Pharma and PhinC Group Collaborate to Bring Predictive Modeling into Early Formulation DevelopmentCorealis Pharma and PhinC Group announced a collaboration to integrate physiologically based biopharmaceutics and pharmacokinetic modeling into oral solid dosage form development. The partnership combines Corealis' formulation expertise with PhinC's predictive modeling to evaluate factors like solubility and food effects earlier. The aim is to reduce clinical development risk and guide formulation decisions with greater confidence.Business Wire BlogCorealis Pharma and PhinC Group Collaborate to Bring Predictive Modeling into Early Formulation DevelopmentCorealis Pharma and PhinC Group announced a collaboration to integrate physiologically based biopharmaceutics and pharmacokinetic modeling into oral solid dosage form development. The partnership combines Corealis' formulation expertise with PhinC's predictive modeling to evaluate factors like solubility and food effects earlier, aiming to reduce clinical development risk.European Pharmaceutical ReviewRottendorf and Corealis collaborate on OSD manufacturingGermany's Rottendorf Pharma and Canada's Corealis Pharma have signed an alliance for oral solid dose (OSD) manufacturing and development, combining capabilities from pre-formulation through to commercial supply. Corealis will lead early-stage R&D and phase I–II clinical supply while Rottendorf will manage phase III, validation, and commercial manufacturing, offering biotech clients a continuous development pathway. The partnership formalizes and extends an existing collaboration with a joint execution and governance framework.BioSpaceBora Pharmaceuticals and Corealis Pharma Forge Strategic Alliance to Deliver Seamless, End-to-End Oral Solid Dose DevelopmentBora Pharmaceuticals and Corealis Pharma announced a strategic alliance to provide end-to-end oral solid dose development and manufacturing services, combining Bora's global commercial infrastructure with Corealis' early-phase formulation expertise. The partnership aims to simplify drug development timelines and reduce outsourcing risk for biotech and pharmaceutical companies by creating a more scalable pathway from clinical phases to commercial launch. The companies will align project management and quality systems to offer a unified service from discovery through commercialization.ContractpharmaBora Pharmaceuticals, Corealis Pharma Partner to Provide OSD ServicesBora Pharmaceuticals Co. Ltd. and Corealis Pharma Inc. have formed a strategic alliance to provide end-to-end oral solid dose development and manufacturing services to biotech and pharmaceutical companies. The collaboration combines Bora's global commercial infrastructure and scale-up capabilities with Corealis' expertise in formulation development and clinical-scale manufacturing, offering a unified pathway from discovery to commercial launch. The alliance aims to simplify the drug development process and reduce outsourcing risk for emerging biotechs seeking to scale therapies from clinical to commercial production.FiercePharmaCDMOs Bora, Corealis link up to provide one-stop shop for oral solid dose production, developmentCDMOs Bora Pharmaceuticals and Corealis Pharma announced a strategic alliance on December 9 to provide an end-to-end contract development and manufacturing offering for oral solid dose drugs. The partnership aims to combine Bora's global commercial infrastructure with Corealis' formulation expertise to streamline the drug development process from discovery to market launch. This move is intended to help biotechs reduce outsourcing risks and accelerate the path to clinical Phase III and commercial production.